Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).
Hideki NakayamaChitose OgawaMasahiro SekimizuHiroyuki FujisakiYoshiyuki KosakaHiroya HashimotoAkiko M SaitoKeizo HoribePublished in: International journal of hematology (2023)